PO.CH01.02 · 化学
靶向蛋白降解剂三元复合物形成的NMR评估
NMR assessment of ternary complex formation by targeted protein degraders
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
靶向蛋白降解(TPD)是一种日益重要的治疗策略,用于靶向以往被认为不可成药的系统。与典型的小分子抑制剂或激动剂不同,TPD通过迫使特定蛋白质与细胞的天然蛋白酶体降解机器邻近,诱导其降解。许多公司正在快速开发新的TPD,多种降解剂已进入临床试验。从化学角度看,需要研究和优化TPD的三个主要方面:1)结合并招募靶蛋白的配体,2)结合E3连接酶的配体,以及3)以正确几何构型将两个配体及其相关蛋白定向排列以实现降解的连接子。TPD呈现出比传统项目更为复杂的先导优化情形,因为它们同时结合两个蛋白质,形成非天然的蛋白质:蛋白质复合物。这些靶蛋白-TPD-E3三元复合物的形成是该领域特别关注的问题。与任何药物开发项目一样,了解TPD如何与其靶蛋白结合的结构细节可提供关键信息,这些信息可能为未来的TPD设计提供新的独特见解。此外,理想的TPD允许降解机器的周转,这意味着这些分子以催化方式发挥作用,在低浓度下降解更多的靶蛋白,从而使三元复合物形成和解离所需的动力学变得复杂。近期研究表明,这些复合物可能本质上是动态的,并涉及非最优相互作用。
核磁共振(NMR)波谱学在研究这些TPD复合物方面具有独特优势,因为它可用于研究溶液中分子的结构和动力学。我们报告了使用NMR表征由TPD同时结合其靶蛋白和E3组成的三元复合物。使用同位素标记的蛋白质,我们首先研究TPD二元复合物,以确定TPD的每一端如何结合,然后评估三元复合物中发生的额外变化。通过这种方法,我们能够区分由配体结合引起的变化和由靶蛋白与E3之间新的蛋白质-蛋白质相互作用引起的变化。我们发现三元复合物中第二个蛋白质的存在会影响TPD与每个蛋白质的结合方式,表明这些实验反映了结合的协同性以及这种协同性可能的结构基础。我们进一步探索了使用跨越一系列具有不同连接子的TPD所获得的NMR数据,结合传统的降解检测,来指导我们对理想化三元复合物结构系综的理解。使用NMR研究三元复合物动力学为下一代TPD的设计和优化提供了一种新策略。我们将公开与本研究相关的所有结构。
查看英文原文 English abstract
Targeted protein degradation (TPD) is an increasingly prominent therapeutic strategy for targeting systems previously thought to be undruggable. Unlike typical small molecule inhibitors or agonists, TPDs induce the degradation of specific proteins by forcing them into proximity with the cell's native proteasomal degradation machinery. Many companies are rapidly developing new TPDs, and several degraders have reached clinical trials. From a chemistry standpoint, there are three main aspects of a TPD to study and optimize: 1) a ligand that binds and recruits a target protein, 2) a ligand that binds an E3 ligase, and 3) a linker that orients the two ligands and their associated proteins at the correct geometry for degradation. TPDs present a more complicated case of lead optimization than traditional programs since they bind simultaneously to two proteins forming a non-native protein:protein complex. The formation of these target protein-TPD-E3 ternary complexes is of particular interest in the field. As in any drug development program, knowing structural details of how TPDs bind to their target proteins provides critical information that may offer new and unique insights into future TPD design. Further, ideal TPDs allow for turnover of the degradation machinery, meaning that these molecules act catalytically to degrade more target protein at low concentrations, which complicates the desired kinetics for the formation and dissolution of ternary complexes. Recent work has shown that these complexes may be fundamentally dynamic and involve non-optimal interactions.
Nuclear magnetic resonance (NMR) spectroscopy is uniquely poised to study these TPD complexes since it can be used to study both the structure and dynamics of molecules in solution. We report our use of NMR to characterize ternary complexes consisting of a TPD bound to both its target protein and the E3. Using isotopically labeled proteins, we first study the TPD binary complexes to establish how each end of the TPD binds before assessing additional changes that occur in ternary complexes. With this approach, we have the capacity to discriminate between changes due to ligand binding and those due to novel protein-protein interactions between the target protein and the E3. We find that the presence of the second protein in the ternary complex affects how the TPD binds to each protein, suggesting that these experiments report on the cooperativity of binding and the possible structural basis of this cooperativity. We further explored the use of NMR data acquired across a series of TPDs with different linkers to guide our understanding of the idealized ternary complex structural ensemble when combined with traditional assays for degradation. The study of ternary complex dynamics using NMR offers a new strategy to allow for the design and optimization of the next generation of TPDs. We will be disclosing all the structures related to this study.
利益披露 Disclosure
E. M. Grasso, None..
D. Fry, None..
N. Panth, None..
Z. Sparta, None..
M. S. Chalasani, None..
A. Haidi, None..
S. Murkli, None..
N. Jain, None.